MetaCap

Faeth Therapeutics (FTH) vs Immuneering (IMRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Faeth Therapeutics (FTH) has outperformed Immuneering (IMRX) over the past year, losing 9.6% versus a loss of 53.7%. Over five years, IMRX leads with a -85.0% price change compared with -95.0% for FTH. Immuneering is the larger company by market cap ($218.9 million vs $203.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FTH-9.64%IMRX-53.70%
+380%+153%-74%
Nov 21, 20251 yearNov 20, 2026
FTH-95.34%IMRX-86.40%
+5%-48%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FTH versus IMRX key metrics
MetricFTHIMRX
Share price$7.88$3.38
Market cap$203.65M$218.90M
1-day change-9.32%-2.03%
YTD return-26.15%-48.63%
1-year return-9.64%-53.70%
5-year return-94.96%-85.00%
EPS (TTM)$-22.50$-0.92
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-21.09M$-56.02M
52-week high$42.14$8.48
52-week low$7.45$3.29
Distance from 52-week high-81.30%-60.14%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+612.56%+402.96%
Average volume500.25K747.66K
Shares outstanding25.84M64.76M
Employees2965
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FTH has outperformed IMRX by 44.1 percentage points over the past year.

About Faeth Therapeutics

FTH stock →

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

About Immuneering

IMRX stock →

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.

Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees

FTH vs IMRX FAQ

Which is bigger, Faeth Therapeutics or Immuneering?

Immuneering (IMRX) is larger, with a market capitalization of $218.90M compared with $203.65M for Faeth Therapeutics (FTH).

Which stock has performed better over the past year, FTH or IMRX?

FTH returned -9.64% over the past 12 months, compared with -53.70% for IMRX (price return, excluding dividends). Past performance does not predict future results.

Are Faeth Therapeutics and Immuneering in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons